Welcome to our dedicated page for Lakewood-Amedex SEC filings (Ticker: LABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lakewood-Amedex Biotherapeutics filings document its status as a Nevada clinical-stage biotechnology company and Nasdaq-listed issuer focused on Bisphosphocin antimicrobial compounds. The company’s S-1 registration materials cover securities registration, business description, capitalization, risk factors, and offering-related disclosures for LABT common stock.
Material-event filings include governance disclosures such as director appointments and board matters reported under Form 8-K. The filing record also identifies public-company information related to corporate structure, pharmaceutical-preparations classification, executive offices, and securities-law reporting obligations.
Lakewood-Amedex Biotherapeutics Inc. filed a prospectus supplement to its Form S-1 incorporating its Form 10-Q for the quarter ended March 31, 2026. The company reported a net loss of $(923,291) for the three months ended March 31, 2026 and cash and cash equivalents of $11,709 as of that date.
The balance sheet shows total assets of $196,343 and total liabilities of $3,037,991, with shares outstanding of 6,995,469 as of March 31, 2026. Subsequent events disclosed include a private sale of Series C Convertible Preferred Stock that closed on April 21, 2026 for gross proceeds of approximately $7.5M (net proceeds ~$6.8M), the automatic conversion of various convertible instruments upon the company’s Nasdaq listing on April 23, 2026, and the filing of a registration statement covering 9,375,000 common shares issuable upon conversion of the Series C Preferred.
Lakewood-Amedex Biotherapeutics Inc. registers 9,375,000 shares of common stock on a Form S-1 prospectus supplement to cover shares issuable upon conversion of its Series C Convertible Preferred Stock. The prospectus supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026.
The Company reported cash and cash equivalents of $11,709 as of March 31, 2026 and a net loss of $923,291 for the three months then ended. The Company completed a private Series C financing that generated gross proceeds of $7.5 million (net proceeds about $6.8 million) in April 2026 and completed its Nasdaq Capital Market listing on April 23, 2026. Management states the net proceeds and debt conversions improve liquidity and are expected to support operations through the fourth quarter of 2026, but notes that substantial doubt about going concern has not been alleviated.
Lakewood-Amedex Biotherapeutics Inc. reported a net loss of $923,291 for the quarter ended March 31, 2026, with no revenue and an accumulated deficit of $54.3 million. Operating expenses rose to $886,750, driven mainly by higher general and administrative costs linked to Nasdaq listing preparation.
Cash and cash equivalents were $11,709 at quarter-end against total liabilities of $3.0 million and a stockholders’ deficit of $2.8 million, leading management to state that substantial doubt exists about the company’s ability to continue as a going concern. After quarter-end, the company completed a $7.5 million Series C Convertible Preferred Stock financing, receiving approximately $6.8 million net, and all Series A and B preferred shares and $1.5 million of convertible notes converted into common stock upon its Nasdaq Capital Market listing. Management believes this funding supports operations through the fourth quarter of 2026 but still anticipates needing additional capital.
Lakewood-Amedex Biotherapeutics Inc. registers 9,647,726 shares of Common Stock for resale, composed of 9,375,000 shares issuable upon conversion of Series C Preferred Stock and 272,726 shares held by RBW Capital Partners LLC.
The prospectus states the company will receive no proceeds from these resales and that sales may occur at fixed, market, negotiated or other prices through underwriters, brokers, agents, or directly by the selling stockholders. The company paid registration expenses; selling stockholders bear selling commissions and transfer taxes.
Lakewood-Amedex Biotherapeutics Inc. director Tucker Joseph Edward received a grant of warrants to acquire 33,784 shares of Common Stock. The warrants carry an exercise price of $10.00 per share and were awarded as a grant/award acquisition, not an open-market purchase.
The warrants vest in four equal tranches of 8,446 warrants on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028, and expire on April 23, 2036. Following this grant, 33,784 derivative securities of this type are reported as directly held.
Lakewood-Amedex Biotherapeutics Inc. director Tucker Joseph Edward filed an initial Form 3 reporting his beneficial ownership in the company. The filing lists his direct holdings of common stock at 0 shares following the reporting date, and shows no reported purchases, sales, or option exercises.
Lakewood-Amedex Biotherapeutics Inc. director Leonard James DeRoma filed an initial Form 3 showing his existing stake in the company. He reports direct ownership of 187,736 shares of common stock.
DeRoma also holds several series of warrants to acquire common stock at exercise prices ranging from $2.13 to $5.92 per share, with expiration dates between 2028 and 2032. The filing reflects current holdings rather than new purchases or sales.
Lakewood-Amedex Biotherapeutics Inc. Chief Medical Officer Thomas Balzer filed an initial ownership report describing his equity stake in the company. He directly holds 255,322 shares of common stock.
He also holds several stock options: rights to buy 168,919 shares of common stock at an exercise price of $2.31 per share expiring on July 1, 2035, and options to buy 46,115, 33,784, and 50,676 shares at an exercise price of $2.13 per share, expiring on March 13, 2034, March 1, 2033, and November 13, 2032, respectively. The filing records these positions as holdings rather than new purchases or sales.
Lakewood-Amedex Biotherapeutics Inc. director and CEO Kelvin Cooper has filed an initial Form 3 detailing his holdings in LABT. He directly holds 300,594 shares of common stock. He also holds several stock options to buy common shares at exercise prices between $2.13 and $2.78 per share, with expiration dates ranging from 2031 to 2035.